The facility will identify the cause of disease in each patient and determine a drug candidate that can potentially cure that disease
Richmond-based life sciences company, SignalChem Lifesciences has opened a new research facility in Bangalore. The research facility will identify the cause of disease in each patient and determine a drug candidate that can potentially cure that disease. It will also increases the value of the company’s therapies and helps increase its intellectual property.
“SignalChem Lifesciences’ expansion into the Indian market is great news for both the company and those working in BC’s technology and life sciences sector,” said Premier Christy Clark. “Because of this research facility expansion, the company will need more employees at its facility in BC. This is a great example of how international economic opportunities are spurring job creation at home.”
“Our province’s biopharmaceutical sector is one of the fastest-growing in Canada, and the opening of this new research facility demonstrates that,” said Advanced Education Minister Virk, who attended the facility’s opening ceremony as part of Premier Clark’s India Trade Mission. “I am proud to see B.C. companies like this one making a global impact by making the necessary connections to expand their businesses into new markets.”
“SignalChem has developed a technology platform to discover new drugs by exploiting protein kinases that are known to cause diseases such as cancer, inflammation or central nervous system disorders,” said Dr Akash Mathur, Chief Business Officer, SignalChem and Resident Director, SignalChem India. “These diseases impact populations world-wide and opening a research and development facility in India is a key part of our plan to address these diseases. Upon success, our plan will be a breakthrough contribution by a Canadian biotech company.”
EP News Bureau – Mumbai
